


# **PANCREATIC CANCER**

## **Is a brutal killer with poor medical treatment options**



**CeaseCancer** developing  
Treatment that brings hope to pancreatic cancer patients

- **Pancreatic cancer** represents a major unmet medical need, with very low survival rates driven by late diagnosis and limited effective treatment options.
- Current therapies-dominated by chemotherapy- offer only modest benefits, particularly in advanced disease.
- There is a pressing need to broaden the therapeutic landscape through the development of novel drugs with new mechanisms of action and innovative treatment strategies, including combinations of agents with complementary efficacy

## Standard of Care Treatments


Disease stage	Treatment	Comment
Early/Resectable disease	<ul style="list-style-type: none"><li>• Surgical resection</li><li>• Adjuvant chemotherapy (FOLFIRINOX or gemcitabine)</li></ul>	Available for limited quantity of patients, as most of the patients diagnosed at metastatic stage
Borderline-resectable/ locally advanced	<ul style="list-style-type: none"><li>• Adjuvant chemotherapy FOLFIRINOX or gemcitabine-based</li></ul>	
Metastatic disease	<ul style="list-style-type: none"><li>• First-line: systemic: FOLFIRINOX or gemcitabine + nab-paclitaxel Choice balances efficacy vs toxicity.</li><li>• Second-line: options after gemcitabine failure: nanoliposomal irinotecan+ 5-FU</li></ul>	Most of patients are diagnosed at metastatic stage

## CeaseCancer


CeaseCancer is a drug candidate derived from human Klotho, a naturally expressed protein with proven tumor-suppressing activity.

- Klotho targets 3 signaling pathways having critical role in cancer:  
IGF-1/PI3K/AKT; Wnt/β-Catenin; TGF-β1
- Preclinical data indicates tumor suppression in various cancer types
  - In-vitro- inhibition of cell proliferation of 3 pancreatic cancer cell lines (Panc1, MiAPaCa2, Colo357)  
Synergy demonstrated with chemotherapy (5FU and Gemcitabine)
  - In-vivo- Inhibition of tumor growth in xenograft models (Athymic nude mice)  
Significantly prolonged survival in transgenic KPC model
- Klotho is a glycoprotein, produced in mammalian cells (CHO).
- Bioavailability in systemic injection administration 47.5% (AUC ip vs iv)  
Tmax 2hours, T1/2 13 hours.

## In-vitro





Cell proliferation inhibited by Klotho



Synergy with chemotherapy in inhibition of Cell proliferation

## In-vivo




Decrease tumor growth in transgenic mice model

## CeaseCancer development

- CeaseCancer drug substance optimization:
  - Increased efficacy in cancer treatment
  - Enhanced production yield
  - Increased bioavailability
  - None immunogenicity confirmed
- Advance through preclinical and clinical development as monotherapy and in combination with standard treatments (chemotherapy PD-L1 blocker).
- CeaseCancer aims to provide an effective and well-tolerated therapy for all stages of pancreatic cancer.
- CeaseCancer intended for first line treatment or second line where other therapies are not efficient or not safe

## Target Product Profile


- Drug for injection (SC or IP)
- Dosage according to prescription
- Prescribed by physician
- Dosage according to clinical data
- Prescribed for people diagnosed with pancreatic cancer



\*Illustration

# Pancreatic Cancer Market Size

- Global pancreatic cancer market is expected to reach 7.7\$bn dollars by 2030 with a CAGR of 14.1%
- There is an urgent need for new therapies
- CeaseCancer's Edge:
  - Targeted therapy with minimal adverse effects
  - Synergy with current treatments
  - Potential expansion to other cancer types
  - Potential for FDA Fast Track designation




## Finance

- The target of the current fundraising round is **3,500,000 USD**
- The funds will enable reaching a key milestone:
  - Completion pre-clinical studies
  - Pre-IND meeting with health authorities (e.g FDA)
  - Initiating preparations for clinical development
- At that point, the engagement of pharma companies is anticipated as well as better access to large funding opportunities

# CeaseCancer

**Treatment that brings hope to pancreatic cancer patients**



**Contact**

**meir.biom@gmail.com**

